Trial · NCT03797560
Comparison of Ba-Duan-Jin and Pregabalin in Patients with Fibromyalgia
NCT03797560, Not applicable, Completed, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Comparison of Ba-Duan-Jin and Pregabalin in Patients with Fibromyalgia. Trials, record NCT03797560. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03797560
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Ba-Duan-Jin and Pregabalin in Patients with Fibromyalgia
- NCT number
- NCT03797560
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 104 participants, actual
- Lead sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Conditions
- Fibromyalgia
- Interventions
- Ba-Duan-Jin, Pregabalin capsule
- First posted
- 2019-01-09
- Last updated
- 2024-10-24
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change of the Visual Analogue Scale (VAS) for pain from baseline. | up to 1 week | Pain VAS, range, 0 to 100 mm, where higher scores indicated the perceived pain to be more severe. |
| Secondary | The change of the revised Fibromyalgia Impact Questionnaire (FIQR) from baseline. | Baseline, week 4, week 8, and week 12. | A self-administered questionnaire with 10 subscales, measuring fibromyalgia symptoms and function domains. FIQR total score ranges from 0 to 100, with higher scores indicating more severe symptoms. |
| Secondary | The change of the Multidimensional Fatigue Inventory-20 (MFI-20) from baseline. | Baseline, week 4, week 8, and week 12. | The Multidimensional Fatigue Inventory-20 (MFI-20) measures fatigue severity. The MFI-20 total score ranges from 0 to 80, with higher scores indicate more severe fatigue. |
| Secondary | The change of the Pittsburgh Sleep Quality Index (PSQI) from baseline. | Baseline, week 4, week 8, and week 12. | Scores on the Pittsburgh Sleep Quality Index (PSQI) range from 0 to 21, with higher scores indicating worse sleep quality. |
| Secondary | The Beck II Depression Inventory (BDI) | Baseline, week 4, week 8, and week 12. | The Beck II Depression Inventory (BDI) assesses the severity of depressive symptoms. Scores range from 0 to 39, with higher scores indicate a greater degree of depression severity. |
| Secondary | The change of the Perceived Stress Scale (PSS) from baseline. | Baseline, week 4, week 8, and week 12. | The Perceived Stress Scale (PSS) is for measuring the perception of stress and current levels of experienced stress. Scores range from 0 to 56, with higher total score indicating a greater degree of symptom severity. |
| Secondary | Global Impression of Change (PGIC) questionnaire evaluated at week 12. | Week 12. | A questionnaire determine any change in overall symptom status from the beginning of the study to its conclusion (score range, 1 \[very much improved\] to 7 \[very much worse). |
| Secondary | The change of the Short Form-36 Health Status Questionnaire (SF-36) from baseline. | Baseline, week 4, week 8, and week 12. | The Short Form-36 Health Status Questionnaire (SF-36), which measured health-related quality of life (range, 0 to 100, with higher scores indicating better perceived health status). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34292537 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03797560
GET https://conductscience.org/api/trials/v1/NCT03797560/registered